US 9,498,467 B2Granted

Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1

AssigneeIncyte Corporation

InventorsLance Howard Leopold, Albert Assad

Life of this patent

Estimating the term…

Abstract

This invention relates to JAK selective inhibitors for use in treatment of chronic neutrophilic leukemia and atypical chronic myeloid leukemia in patients.

Claims20

Dependent claims

A method of treating a leukemia selected from chronic neutrophilic leukemia and atypical chronic myeloid leukemia in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a selective JAK1 inhibitor.

Dependencies are inferred from the claim text.

Facts

Application: 14/725,594Filed 29 May 2015 · us provisional application
Priority: 30 May 2014
Published: US 2015/0342952 A13 Dec 2015
Granted: 22 Nov 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…
A61K 9/00
Medicinal preparations characterised by special physical form
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/4155
1,2-Diazoles: non condensed and containing further heterocyclic rings

Family

Application62/005,492Us provisional application · filed 30 May 2014
US 2015/0342952 A1Pre-grant publication · published 3 Dec 2015
US 9,498,467 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results